Richard Gilbertson elected to EMBO membership
Senior Group Leader,Ā Professor Richard Gilbertson, has been elected a member of the European Molecular Biology Organisation (EMBO) in recognition of his high-quality life science research.
Gilbertson is one of 67 life scientists to be elected this year, joining the community of more than 1,900 members in Europe and beyond.
āThe new EMBO Members and Associate Members are exceptional scientists, who carry out leading research across a variety of fields, ranging from cell biology and cancer to vaccine development and machine learning,ā says EMBO Director Fiona Watt. āI am delighted to welcome them to EMBO, and I know that they will enrich the life of the organization immensely.ā
Professor Richard Gilbertson said āIt is such an honour to have been elected toĀ EMBOĀ and be part of this incredible group of scientists and colleagues from across Europe. I very much hope to continue to promote international collaborations and interactions through my membership of this terrific organisation.ā
Members provide guidance and support for EMBO activities, for example by evaluating funding applications, serving on EMBO Council and committees, or joining the editorial boards of EMBO Press journals. Through their involvement, members help to shape the direction of life sciences, foster the careers of young researchers, and strengthen the research communities in Europe and beyond.
New members are nominated and elected by the existing EMBO Membership. The annual process ensures a broad scope with the flexibility to expand into newly emerging fields in the life sciences.
EMBO will formally welcome the new members at the annual Membersā Meeting in Heidelberg between 26 and 28 October 2022.
An online directory listing all members, their affiliations, and subject areas is availableĀ here.
Related News
See all news-
New immune pathway offers treatment hope for childhood brain tumours
3rd February 2026
A newly discovered immune pathway could lead to gentler treatments for multiple childhood brain cancers, according to new research from our Gilbertson Group published today in Nature Genetics.
Find out more -
Targeting paused cells could improve chemotherapy for lung and ovarian cancers
3rd February 2026
New research published today in Nature Aging by scientists at the University of Cambridge sheds light on why some lung and ovarian cancers stop responding to chemotherapy, and how this resistance might one day be prevented.
Find out more -
Hot flush treatment has anti-breast cancer activity, study finds
5th January 2026
A drug mimicking the hormone progesterone has anti-cancer activity when used together with conventional anti-oestrogen treatment for women with breast cancer, a new Cambridge-led trial has found.
Find out more